Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.36 HKD | +2.16% |
|
+1.29% | -64.46% |
Jun. 05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
Jun. 05 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.46% | 275M | |
+23.50% | 45.01B | |
+47.19% | 40.96B | |
-5.16% | 38.62B | |
+36.37% | 32.6B | |
-7.79% | 27.49B | |
+18.06% | 27.17B | |
+47.29% | 14.61B | |
+41.91% | 12.95B | |
-1.02% | 11.36B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab to Proceed With Australian Trials of Anti-Tumor Medication